American Heart Association

Half of patients denied insurance coverage of new cholesterol drugs

By AMERICAN HEART ASSOCIATION NEWS

A pair of cholesterol-lowering drugs called PCSK9 inhibitors were controversial as soon as they hit the market in 2015. They cost an average $14,300 a year, and prescriptions require prior authorization by health insurance companies — which a new study shows isn’t a guarantee.

Only 47 […]

October 30th, 2017|Categories: Cholesterol, Health, Patients, Research|Tags: , , , , , |Comments Off on Half of patients denied insurance coverage of new cholesterol drugs

New drugs slash bad cholesterol

By AMERICAN HEART ASSOCIATION NEWS

Editor’s note: This is one in a 10-part series of the top medical research advances in 2015 as determined by American Heart Association volunteer and staff leaders.

The blockbuster drugs known as statins are teaming with a new medication to lower the level of bad LDL […]

Powerful cholesterol drug awaits FDA’s decision

By AMERICAN HEART ASSOCIATION NEWS

A second in a new class of drugs that sharply lowers cholesterol is set for federal approval by Thursday – a “game-changer” for the hardest-to-treat patients who are in danger of heart attacks and strokes.

For people with familial hypercholesterolemia, or FH, a genetic condition that […]

August 26th, 2015|Categories: Health|Tags: , , , |Comments Off on Powerful cholesterol drug awaits FDA’s decision

FDA approves new cholesterol drug

By AMERICAN HEART ASSOCIATION NEWS

For the first time in decades, the U.S. Food and Drug Administration on Friday approved a major new class of medicines to lower cholesterol, and thereby protect against heart attacks.

Praluent (alirocumab) from Sanofi and Regeneron Pharmaceuticals received approval and a second drug, Repatha (evolocumab) from […]

July 24th, 2015|Categories: Health|Tags: , , |4 Comments